|
Genentech Prohibits Sales of Avastin to Compounding Pharmacies
To prevent ophthalmologists from substituting wet age-related macular degeneration (AMD) treatment Lucentis with oncologic Avastin, Genentech is prohibiting wholesalers from distributing Avastin to compounding pharmacies that repackage the cancer agent and sell it as an AMD treatment, the company announced Oct. 11. Genentech produces both products.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives